补肾祛邪法治疗慢性乙型肝炎的临床研究

注册号:

Registration number:

ChiCTR-TRC-12002190 

最近更新日期:

Date of Last Refreshed on:

2015-08-13 20:55:03 

注册时间:

Date of Registration:

2012-03-14 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

补肾祛邪法治疗慢性乙型肝炎的临床研究

Public title:

A Clinical Study of theTraditional Chinese Formula of Bu Shen Qu Xie on Chronic Hepatitis B

注册题目简写:

English Acronym:

研究课题的正式科学名称:

补肾祛邪法治疗慢性乙型肝炎的临床研究

Scientific title:

A Clinical Study of theTraditional Chinese Formula of Bu Shen Qu Xie on Chronic Hepatitis B

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

李晓东 

研究负责人:

盛国光 

Applicant:

Xiaodong Li 

Study leader:

Guoguang Sheng 

申请注册联系人电话:

Applicant telephone:

+86 13908658127

研究负责人电话:

Study leader's
telephone:

+86 13317199890

申请注册联系人传真 :

Applicant Fax:

+86 27 88920956

研究负责人传真:

Study leader's fax:

+86 27 88920956

申请注册联系人电子邮件:

Applicant E-mail:

lixiaodong555@126.com

研究负责人电子邮件:

Study leader's E-mail:

sguo53@yahoo.com.cn

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

湖北省武汉市武昌区花园山四号(湖北省中医院肝病办公室)

研究负责人通讯地址:

湖北省武汉市武昌区花园山四号(湖北省中医院肝病办公室)

Applicant address:

4 Huayuanshan, Wuchang District, Wuhan, Hubei, China

Study leader's address:

4 Huayuanshan, Wuchang District, Wuhan, Hubei, China

申请注册联系人邮政编码:

Applicant postcode:

430061

研究负责人邮政编码:

Study leader's postcode:

430061

申请人所在单位:

湖北省中医院

Applicant's institution:

Hubei Provincial Traditional Chinese Medical Hospital

研究负责人所在单位:

Affiliation of the Leader:

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

HBZYY-2012-CO2

伦理委员会批件附件:

Approved file of Ethical Committee:

批准本研究的伦理委员会名称:

湖北省中医院伦理委员会

Name of the ethic committee:

The ethics committee of Hubei Provincial Traditional Chinese Medical Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2012-04-18 00:00:00

伦理委员会联系人:

Contact Name of the ethic committee:

伦理委员会联系地址:

Contact Address of the ethic committee:

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

湖北省中医院

Primary sponsor:

Hubei Provincial Traditional Chinese Medical Hospital

研究实施负责(组长)单位地址:

湖北省武汉市武昌区花园山四号

Primary sponsor's address:

4 Huayuanshan, Wuchang District, Wuhan, Hubei, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

北京

市(区县):

Country:

China

Province:

Beijing

City:

单位(医院):

国家中医药管理局

具体地址:

北京市东城区工体西路1号

Institution
hospital:

State Administration of traditional Chinese Medicine of China

Address:

1 West Gongti Road, Dongcheng District, Beijing, China.

经费或物资来源:

国家中医药管理局

Source(s) of funding:

State Administration of traditional Chinese Medicine

研究疾病:

慢性乙型肝炎  

Target disease:

Chronic Hepatitis B

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

评价“补肾祛邪法”辨证加味联合恩替卡韦治疗HBeAg阴性慢性乙型肝炎的有效性和安全性,获得较高级别的临床证据。  

Objectives of Study:

To evaluate the efficacy and safety of the "Bu Shen Qu Xie" united entecavir treatment of HBeAg-negative chronic hepatitis B,and access to a higher level of clinical evidence.

药物成份或治疗方案详述:

恩替卡韦片;中药颗粒剂 ;中药安慰颗粒剂 

Description for medicine or protocol of treatment in detail:

entecavir; Chinese medicine granules; Chinese medicine placebo granules 

纳入标准:

Inclusion criteria

排除标准:

①年龄18岁以下或65岁以上;②排除同时或重叠感染其他类型病毒性肝炎; ③经检查证实由药物中毒、乙醇中毒等因素所致的肝炎及自身免疫性肝炎;④已诊断重度肝炎、重型肝炎/肝衰竭、肝硬化、肝癌,以及严重的心脑血管、肺、肾、内分泌和造血系统严重原发性疾病、精神病患者;⑤妊娠或准备妊娠的妇女,哺乳期妇女;⑥过敏体质,或对多种药物过敏者;⑦半年内使用过干扰素抗病毒药。

Exclusion criteria:

1. Male and female aged below 18 or above 65 years old;
2. Exclude the same time or overlap with other types of viral hepatitis infection;
3. Confirmed as caused by drug intoxication, alcohol poisoning, hepatitis and autoimmune hepatitis;
4. Patients who have been diagnosed with severe hepatitis, severe hepatitis / liver failure, cirrhosis, liver cancer and have serious primary disease in cardiovascular and cerebrovascular, kidney, lung, endocrine system, hematopoietic system of severe primary disease and patients with mental disease;
5. Pregnant or lactating women;
6. allergic to drug;
7. Patients who have been used interferon antiviral within six months.

研究实施时间:

Study execute time:

From 2012-05-20 00:00:00 To 2014-06-30 00:00:00  

征募观察对象时间:

Recruiting time:

From 2012-05-01 00:00:00 To 2013-05-01 00:00:00

干预措施:

Interventions:

组别:

治疗组

样本量:

310

Group:

Group A

Sample size:

干预措施:

补肾祛邪颗粒剂2次/日,冲服,治疗48周;恩替卡韦片 0.5mg/次,治疗48周

干预措施代码:

Intervention:

Diwuyanggan Granules orally taken twice daily for 48 weeks; Entecavir 0.5mg orally taken once daily for 48 weeks.

Intervention code:

组别:

对照组

样本量:

310

Group:

Group B

Sample size:

干预措施:

中药安慰颗粒剂,2次/日,冲服,治疗48周;恩替卡韦片 0.5mg/次,治疗48周

干预措施代码:

Intervention:

Placebo Granules orally taken twice daily for 48 weeks; Entecavir 0.5mg orally taken once daily for 48 weeks

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

湖北 

市(区县):

武汉市 

Country:

China

Province:

Hubei

City:

Wuhan

单位(医院):

湖北省中医院 

单位级别:

三级甲等 

Institution
hospital:

Hubei Provincial Traditional Chinese Medical Hospital

Level of the institution:

Tertiary A hospital

国家:

中国

省(直辖市):

上海 

市(区县):

 

Country:

China

Province:

Shanghai

City:

单位(医院):

上海中医药大学附属曙光医院 

单位级别:

三级甲等 

Institution
hospital:

Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine

Level of the institution:

Tertiary A hospital

国家:

中国

省(直辖市):

湖南 

市(区县):

 

Country:

China

Province:

Hunan

City:

单位(医院):

湖南中医药大学附属第一医院 

单位级别:

三级甲等 

Institution
hospital:

First Affiliated Hospital of Hunan University of Traditional Chinese Medicine

Level of the institution:

Tertiary A hospital

国家:

中国

省(直辖市):

广西 

市(区县):

 

Country:

China

Province:

Guangxi

City:

单位(医院):

广西中医学院第一附属医院 

单位级别:

三级甲等 

Institution
hospital:

First Affiliated Hospital of Guangxi College of Traditional Chinese Medicine

Level of the institution:

Tertiary A hospital

国家:

中国

省(直辖市):

广东 

市(区县):

 

Country:

China

Province:

Guangdong

City:

单位(医院):

广东省中医院 

单位级别:

三级甲等 

Institution
hospital:

Guangdong Provincial Hospital

Level of the institution:

Tertiary A hospital

国家:

中国

省(直辖市):

深圳 

市(区县):

 

Country:

China

Province:

Shenzhen

City:

单位(医院):

深圳市中医院 

单位级别:

三级甲等 

Institution
hospital:

Shenzhen Municipal Hospital of Traditional Chinese Medicine

Level of the institution:

Tertiary A hospital

国家:

中国

省(直辖市):

北京 

市(区县):

 

Country:

China

Province:

Beijing

City:

单位(医院):

解放军302医院 

单位级别:

三级甲等 

Institution
hospital:

People's Liberation Army 302 Hospital

Level of the institution:

Tertiary A hospital

国家:

中国

省(直辖市):

北京 

市(区县):

 

Country:

China

Province:

Beijing

City:

单位(医院):

北京地坛医院 

单位级别:

三级甲等 

Institution
hospital:

Beijing Ditan Hospital

Level of the institution:

Tertiary A hospital

国家:

中国

省(直辖市):

山东 

市(区县):

 

Country:

China

Province:

Shandong

City:

单位(医院):

山东省中医院 

单位级别:

三级甲等 

Institution
hospital:

Shandong Provincial Hospital

Level of the institution:

Tertiary A hospital

国家:

中国

省(直辖市):

陕西 

市(区县):

 

Country:

China

Province:

Shanxi

City:

单位(医院):

陕西中医学院附属医院 

单位级别:

三级甲等 

Institution
hospital:

Shanxi College of Traditional Chinese Medicine Affiliated Hospital

Level of the institution:

Tertiary A hospital

国家:

中国

省(直辖市):

深圳 

市(区县):

 

Country:

China

Province:

Shenzhen

City:

单位(医院):

深圳市第三人民医院 

单位级别:

三级甲等 

Institution
hospital:

Third People's Hospital of Shenzhen City

Level of the institution:

Tertiary A hospital

国家:

中国

省(直辖市):

厦门 

市(区县):

 

Country:

China

Province:

Xiamen

City:

单位(医院):

厦门市中医院 

单位级别:

三级甲等 

Institution
hospital:

Xiamen City Hospital of Traditional Chinese Medicine

Level of the institution:

Tertiary A hospital

国家:

中国

省(直辖市):

武汉 

市(区县):

 

Country:

China

Province:

Wuhan

City:

单位(医院):

武汉市医疗救治中心 

单位级别:

三级甲等 

Institution
hospital:

Medical treatment center in Wuhan City

Level of the institution:

Tertiary A hospital

国家:

中国

省(直辖市):

北京 

市(区县):

 

Country:

China

Province:

Beijing

City:

单位(医院):

北京佑安医院 

单位级别:

三级甲等 

Institution
hospital:

Beijing You An Hospital

Level of the institution:

Tertiary A hospital

国家:

中国

省(直辖市):

北京 

市(区县):

 

Country:

China

Province:

Beijing

City:

单位(医院):

北京中医药大学东直门医院 

单位级别:

三级甲等 

Institution
hospital:

Beijing University of Chinese Medicine, Dongzhimen Hospital

Level of the institution:

Tertiary A hospital

测量指标:

Outcomes:

指标中文名:

HBVDNA

指标类型:

主要指标

Outcome:

HBVDNA

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

乙肝全套

指标类型:

主要指标

Outcome:

HBV antigen and antibody complete set test

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

B超

指标类型:

主要指标

Outcome:

Liver morphological change

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

肝脏穿刺

指标类型:

主要指标

Outcome:

Liver Biopsy

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

肝功能

指标类型:

主要指标

Outcome:

Liver Function index

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

慢性乙型肝炎生存质量量表

指标类型:

主要指标

Outcome:

Quality of life scale for Chronic Hepatitis

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

Liver

人体标本去向

使用后销毁  

说明

2

Fate of sample:

Destruction after use  

Note:

2

征募研究对象情况:

Recruiting status:

结束

/Completed

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 65 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

区组随机

Randomization Procedure (please state who generates the random number sequence and by what method):

Randomization

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

患者 是 研究者 是

Blinding:

Researcher: Yes Patient: Yes

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

湖北省中医院

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Hubei Provincial Traditional Chinese Medical Hospital

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

湖北省中医院

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Hubei Provincial Traditional Chinese Medical Hospital

数据与安全监察委员会:

Data and Safety Monitoring Committee:

注册人:

Name of Registration:

 2012-05-23 00:00:00